158 related articles for article (PubMed ID: 17712588)
1. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
[TBL] [Abstract][Full Text] [Related]
3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
4. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
[TBL] [Abstract][Full Text] [Related]
5. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
6. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Kim JY; Chung EJ; Park SW; Lee WY
Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
[TBL] [Abstract][Full Text] [Related]
7. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
[TBL] [Abstract][Full Text] [Related]
8. Pergolide-associated valvular heart disease.
Waller EA; Kaplan J
Compr Ther; 2006; 32(2):94-101. PubMed ID: 16845152
[TBL] [Abstract][Full Text] [Related]
9. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
10. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
[TBL] [Abstract][Full Text] [Related]
11. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
[TBL] [Abstract][Full Text] [Related]
12. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
Dewey RB; Reimold SC; O'Suilleabhain PE
Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
[TBL] [Abstract][Full Text] [Related]
13. The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
Ooba N; Yamaguchi T; Kubota K
Drug Saf; 2011 Apr; 34(4):329-38. PubMed ID: 21417505
[TBL] [Abstract][Full Text] [Related]
14. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
[TBL] [Abstract][Full Text] [Related]
15. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study.
Peralta C; Wolf E; Alber H; Seppi K; Müller S; Bösch S; Wenning GK; Pachinger O; Poewe W
Mov Disord; 2006 Aug; 21(8):1109-13. PubMed ID: 16622856
[TBL] [Abstract][Full Text] [Related]
16. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology.
Droogmans S; Franken PR; Garbar C; Weytjens C; Cosyns B; Lahoutte T; Caveliers V; Pipeleers-Marichal M; Bossuyt A; Schoors D; Van Camp G
Eur Heart J; 2007 Sep; 28(17):2156-62. PubMed ID: 17636306
[TBL] [Abstract][Full Text] [Related]
17. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease.
Nakaoka S; Ishizaki T; Urushihara H; Satoh T; Ikeda S; Morikawa K; Nakayama T
Intern Med; 2011; 50(7):687-94. PubMed ID: 21467699
[TBL] [Abstract][Full Text] [Related]
18. Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
Ozer F; Tiras R; Cetin S; Ozturk O; Aydemir T; Ozben S; Meral H; Kizkin S; Bader H; Ozben B
J Clin Neurosci; 2009 Jan; 16(1):83-7. PubMed ID: 19014887
[TBL] [Abstract][Full Text] [Related]
19. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
[TBL] [Abstract][Full Text] [Related]
20. [Cardiac valvulopathy and dopamine agonist].
Grandas F
Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
